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ABSTRACT
The purpose of this study was to evaluate the effect of obesity and obesity-
associated factors on the outcomes of patients with cervical cancer. Outcomes were 
evaluated in 591 patients with FIGO Ib to IV cervical cancer treated uniformly with 
definitive radiation. Patients were stratified into 3 groups based upon pretreatment 
Body Mass Index (BMI): A ≤ 18.5; B 18.6 – 34.9; and C ≥ 35. The 5-year freedom from 
failure rates were 58, 59, and 73% for BMI groups A, B, and C (p = 0.01). Overall survival 
rates were 50, 59, and 68%, respectively (p = 0.02). High expression of phosphorylated 
AKT (pAKT) was associated with poor outcomes only in non-obese patients. Obese 
patients with PI3K pathway mutant tumors had a trend toward favorable outcomes, 
while a similar effect was not observed in non-obese patients. Compared to similar 
tumors from non-obese hosts, PIK3CA and PTEN mutant tumors from obese patients 
failed to express high levels of phosphorylated AKT and its downstream targets. These 
results show that patients with obesity at the time of diagnosis of cervical cancer 
exhibit improved outcomes after radiation. PI3K/AKT pathway mutations are common 
in obese patients, but are not associated with activation of AKT signaling.
INTRODUCTION
Increasing body mass index (BMI) has been 
associated with increased cancer-related mortality. 
Calle and colleagues found that overweight women 
had an increased risk of death from all causes and that 
the death rate in women from cervical cancer increased 
with increasing BMI [1]. In the UK’s Million Women 
cohort study, Reeves and associates found that cervical 
cancer incidence and mortality increased with increasing 
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BMI [2]. However, Xu and colleagues reported results 
from the Cancer Genome Atlas (TCGA) showing lower 
mortality in cervical cancer patients with higher BMI 
values [3]. Although the analysis by Xu using TCGA data 
demonstrated lower mortality in cervical cancer patients 
with higher BMI values, these patients were treated 
with a variety of techniques and outcome data was not 
prospectively collected. The aim of the current study was 
to use a well-annotated clinical database to evaluate the 
association of obesity and cervix cancer patient outcomes 
after uniform treatment with curative intent radiation. 
A prospectively collected institutional tumor bank was 
used to determine whether obesity associated factors 
(metformin, insulin, and PI3K/AKT signaling) were 
associated with outcomes in the context of definitive 
radiation treatment.
RESULTS
Patient baseline characteristics are shown in Table 
1. There were no significant differences in the traditional 
patient- and tumor-related prognostic factors of age, 
tumor stage, pretreatment 18F-fluoro-deoxy-glucose 
(FDG) positron emission tomography (PET) lymph node 
(LN) status and histology relative to the patient’s BMI. 
Patients with a high BMI were more likely to have Type II 
diabetes, take metformin, and take insulin. The distribution 
of patient BMI is shown in Figure 1. We have previously 
reported that cervical tumor FDG uptake quantified by 
Standardized Uptake Value (SUV) on pretreatment FDG-
positron emission tomography (PET) scans is associated 
with poor prognosis [4]. To determine whether obesity 
remained a significant predictive factor in the setting of 
other known pretreatment risk factors, including cervical 
tumor SUV, a multivariate analysis was performed (Table 
2). Cox proportional hazards modeling demonstrated that 
obesity remained significant in a model that included 
clinical stage, cervix tumor SUV and pretreatment lymph 
node status. There was no association between patient 
obesity and individual pretreatment risk factors including 
clinical stage, lymph node status and cervix tumor SUV. 
Similarly, there was no association between tumor human 
papilloma virus (HPV) status and patient obesity (data not 
shown).
Overall survival outcomes are shown in Figure 2A. 
Overall survivals at 5 years were significantly improved 
for obese patients treated with radiation (50, 59, and 68% 
for BMI groups A, B, and C p = 0.02). Corresponding 
5-year FF rates were 58, 59, and 73% respectively (Figure 
2B, p = 0.01). Metformin use was more common in BMI 
Group C (15%) than in Groups A (6%) or B (3%); however 
FF and OS were not affected by metformin use (Figure 
2C and 2D). Similarly, FF and OS were not affected by 
diabetes or insulin use (Figures 2E-2H).
We have previously reported that increased 
expression of phosphorylated AKT is associated with 
poor prognosis after definitive radiation for cervical 
cancer [5]. To determine whether activation of AKT 
signaling was associated with outcome in obese 
versus non-obese patients, we analyzed expression of 
phosphorylated AKT (pAKT) by immunohistochemistry 
(IHC) using a commercially available antibody specific 
for AKT phosphorylated at serine 473 (S473). High pAKT 
expression by IHC was not associated with a statistically 
significant decrease in FF amongst all-comers (p=0.17, 
Figure 3A). High pAKT expression was associated with 
significantly reduced FF only in patients with BMI ≤ 30 
(p=0.05, Figure 3B). In contrast, in the cohort of patients 
Figure 1: Patient characteristics and BMI distribution of the study population. Pretreatment Body Mass Index (BMI) 
distribution histogram for 591 patients treated with radiation for cervical cancer.
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with BMI > 30, high pAKT expression was not associated 
with FF (p=0.76, Figure 3C). These results imply that 
the significance of pAKT expression as a biomarker for 
poor outcome after radiation treatment depends on patient 
obesity. For patients with a low BMI, expression of 
pAKT is predictive of poor outcome after irradiation. For 
obese patients, pAKT expression alone is not predictive, 
suggesting that downstream signals from AKT have less 
Table 1: Patient baseline characteristics
All
N = 591
BMI A
≤ 18.5
N = 33
BMI B
18.6 – 34.9
N = 427
BMI C
≥ 35
N = 131
p-value
Age
 Range 23-92 32-81 23-92 24-83 N.S.
 Mean 52 52 52 52
Stage
 I (Ia1, Ia2, Ib1, Ib2) 200 9 131 60 N.S.
 II (IIa, IIb) 237 13 175 49
 III (IIIa, IIIb) 139 9 110 20
 IV (IVa, IVb) 15 2 11 2
BMI
 Range 13-57 13-18.5 18.6-34.9 35-57 N.A.
 Median 27.5 18 26.1 40.5
PET lymph nodes (LN)
 None 261 11 182 68 N.S.
 Pelvis 240 18 178 44
 Pelvis & Para-artic 84 3 62 19
 P+P+SCV 6 1 5 0
Histology
 Squamous 502 29 368 105 N.S.
 Adenocarcinoma 60 2 37 21
 Other 29 2 22 5
Metformin
 Yes 35 2 14 19 <0.0001
 No 544 31 405 108
 Unknown 12 0 8 4
Insulin
 Yes 30 1 12 17 <0.0001
 No 549 32 407 110
 Unknown 12 0 8 4
Type II
 Yes 75 2 33 40 <0.0001
 No 504 31 386 87
 Unknown 12 0 8 4
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impact on radiation responses when the patient is obese 
and the resulting tumor environment is influenced by the 
obese state.
Somatic mutations in the PI3K/AKT signaling 
pathway have been identified in many cancers and are 
thought to promote inappropriate activation of AKT 
signaling. To identify somatic mutations in PIK3CA 
and PTEN (including PTEN copy number (CN) loss) in 
our patient population, targeted exome sequencing was 
performed on 91 pretreatment cervical tumor biopsies. 
The most common PIK3CA mutation was E545K in 
both groups (Table 3 and Figure 4A). PIK3CA and PTEN 
mutations were identified in 30 samples, 14 from non-
obese patients and 16 from obese patients. Previous work 
from our group identified alterations in expression of 
genes from the PI3K/AKT pathway that were associated 
with incomplete metabolic response after chemoradiation 
in cervical cancer, and preliminary data demonstrated an 
association between PIK3CA activating mutations and 
inferior recurrence-free survival outcome after radiation 
[5, 6]. For this reason we compared FF outcomes for obese 
and non-obese patients with and without PI3K pathway 
mutations. There was a trend toward improved FF for 
obese patients with PI3K pathway mutations (p=.09) 
(Figure 4B). In contrast, non-obese patients with PI3K 
pathway mutations experienced similar if not inferior FF 
outcomes compared to non-obese patients without PI3K 
pathway mutations (p=.23) (Figure 4C).
We then used reverse phase protein phosphorylation 
data from the Cancer Genome Atlas Project to test whether 
phosphorylation of AKT and AKT downstream targets was 
different in cervical tumors from patients who are obese 
versus non-obese. Among TCGA cervical cancer patients, 
obesity showed a trend toward improved overall survival, 
however this result did not reach statistical significance (p 
=.07, Figure 5). We then specifically examined whether 
protein phosphorylation patterns for AKT and downstream 
targets of AKT were different in PIK3CA and PTEN 
mutant tumors from obese versus non-obese hosts. In non-
obese hosts, PIK3CA and PTEN mutant tumors displayed 
statistically significant increased phosphorylation of AKT 
at 2 key sites critical for full activation of AKT kinase 
activity, S473 and threonine 308 (T308) (Figure 6). In 
contrast, no increase in AKT phosphorylation at either 
site was observed for PIK3CA and PTEN mutant tumors 
from patients with BMI > 35. In addition, phosphorylation 
of PRAS40 and TUBERIN, two downstream direct 
targets of AKT kinase, was increased in PIK3CA and 
PTEN mutant tumors from non-obese hosts (p=.03 and 
p=.02, respectively), but phosphorylation of PRAS40 
and TUBERIN was not increased in PIK3CA and PTEN 
mutant tumors from patients with BMI > 35. It should be 
noted, however, that not all AKT targets demonstrated 
differences in phosphorylation based upon obesity of the 
host (Figure 6 GSK3 and data not shown).
DISCUSSION
In this study, we report that severely obese patients 
with cervical cancer treated with radiation have a better 
survival outcome than obese, normal, and underweight 
patients. Most investigators report that obese patients 
are at a higher risk for developing certain types of cancer 
and that their survival outcomes are poor when compared 
to normal weight patients. The mechanisms for poor 
outcomes in obese patients include insulin resistance, 
hyperinsulinemia, inflammatory responses, and increased 
bio-availability of steroid hormones. Our clinical data 
for cervical cancer are unique in that obese patients, 
specifically severely obese patients (BMI > 35) treated 
with definitive radiation, have favorable survival outcomes 
after treatment. Our study represents the largest reported 
series to date of clinical outcomes related to obesity for 
cervical cancer patients.
Metformin use has been reported to both decrease 
cancer risk and decrease cancer mortality. In our study, 
the severely obese women with cervical cancer, outcomes 
were not affected by metformin use, type II diabetes, 
or insulin use. Thus, the favorable outcome results in 
severely obese patients cannot be explained by diabetes 
or metformin use. Therefore, we explored other potential 
biological explanations for the difference in survival 
outcomes related to obesity.
Previous work from our group identified alterations 
in expression of genes from the PI3K/AKT pathway 
that were associated with incomplete metabolic 
Table 2: Final results of proportional hazards model for recurrence
Multivariate hazard ratio (95% CI) P-value
Lymph Node Status (LN+ vs LN-) 1.692 (1.338, 2.320) 0.0010
Cervix Standardized Uptake Value (SUV) 1.020 (1.002, 1.037) 0.0280
Stage I (ref) 0.0018
Stage II 1.436 (0.982, 2.100)
Stage III 2.117 (1.413, 3.171)
Stage IV 2.630 (1.039, 6.658)
BMI >= 35 vs BMI < 35 0.655 (0.439, 0.979) 0.0388
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response after chemoradiation in cervical cancer, and 
preliminary data demonstrated an association between 
PIK3CA activating mutations and inferior disease-free 
survival outcome after radiation [5, 6]. Examination of 
the specific mutations present in obese and non-obese 
patients (Table 3) demonstrated roughly equal numbers 
Figure 2: Survival outcomes separated by obesity and metformin use. (A) Kaplan Meier curve for overall survival for patients 
in BMI group: A ≤ 18.5 (black); B 18.6 – 34.9 (red); and C ≥ 35 (green), p = 0.02. C. (B) Kaplan Meier curve for freedom from failure for 
patients in BMI group: A ≤ 18.5 (black); B 18.6 – 34.9 (red); and C ≥ 35 (green), p = 0.01. (C) Kaplan Meier curve for overall survival for 
patients from BMI group C with (red) and without (black) metformin use (p=0.71) (D) Kaplan Meier curve for freedom from failure for 
patients from BMI group C with (red) and without (black) metformin use (p=0.83). (E) Kaplan Meier curve for overall survival for patients 
from BMI group C with (red) and without (black) insulin use (p=0.33). (F) Kaplan Meier curve for freedom from failure for patients from 
BMI group C with (red) and without (black) insulin use (p=0.43). (G) Kaplan Meier curve for overall survival for patients from BMI group 
C with (red) and without (black) a diagnosis of diabetes (p=0.62). (H) Kaplan Meier curve for freedom from failure for patients from BMI 
group C with (red) and without (black) a diagnosis of diabetes (p=0.59).
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Figure 3: Immunohistochemistry for pAKT and outcome in obese versus non obese patients. (A) Freedom from failure for 
all patients, high versus not high pAKT IHC, p = 0.17. (B) Freedom from failure, BMI ≤ 30, high versus not high pAKT IHC, p=0.05. (C) 
Freedom from Failure, BMI > 30, high versus not high pAKT IHC, p=0.76.
Figure 4: PI3K pathway mutations and outcome in obese versus non obese patients. (A) Distribution of PIK3CA somatic 
mutations in obese and non-obese patients. (B) Kaplan Meier curves for freedom from failure in obese patients (BMI > 30) with (red) and 
without (black) PIK3CA and PTEN mutations, p =.09. (C) Kaplan Meier curves for freedom from failure in non-obese patients (BMI < 30) 
with (red) and without (black) PIK3CA and PTEN mutations, p = 0.23.
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of PIK3CA activating and PTEN inactivating mutations 
between the two groups. The most common PIK3CA 
mutation was E545K in both groups. E545K is a common 
cancer-associated mutation in the helical domain of the 
p110alpha subunit of PI3K, which results in constitutive 
PI3K activity and has been reported to transform cells and 
enhance tumorigenic phenotypes [7–9]. A number of less 
well characterized mutations in PIK3CA were identified in 
our data set, including C420R, which has been reported to 
induce oncogenic transformation by promoting membrane 
binding of p110alpha [10]. The most frequent mechanism 
of PTEN mutation was PTEN copy number deletion. 
PTEN R130Q/G point mutations and a single frameshift 
at T319 were identified in the obese patient group.
Although obese patients had high rates of PIK3CA 
and PTEN mutations, obesity was not associated with 
increased expression of pAKT, raising the possibility 
that PIK3CA and PTEN mutations in obese patients 
Table 3: PIK3CA, PTEN and BMI in the WUSTL sequencing cohort
Sample PIK3CA PTEN BMI HPV subtype
705973 p.E545K CN Loss 18.3 HPV 52
760832 p.E542K WT 18.8 HPV 16
724788 p.E39K WT 23.2 HPV 16, HPV 18
727879 p.E545K WT 23.2 HPV 16
740838 p.E545K WT 23.2 HPV 18
704786 p.E542Q WT 23.7 HPV 16
707755 WT CN Loss 24 HPV 16
734998 p.E545k, p.Q879* WT 24.4 HPV 31
733024 p.H1047R WT 25.2 HPV 16
703822 p.E545K WT 25.5 HPV 16
722396 p.E545K WT 25.5 HPV 16
710808 WT CN Loss 26 Many
704849 WT CN Loss 26.1 HPV 16
711380 WT CN Loss 26.6 Negative
736133 p.E545K WT 31.6 HPV 16
720170 WT p.R233* 31.8 Negative
704821 p.E81K WT 32.1 HPV 16
704956 p.E493K, p.E476Q, p.E494K WT 35 HPV 58
728723 p.E81K WT 35.7 HPV 16
720059 p.E545K WT 37.3 Negative
714694 p.E545.K WT 37.6 HPV 16
731976 WT p.R130Q 39.1 HPV 16
733384 WT CN Loss 39.7 HPV 33
714960 p.E542K WT 39.9 HPV 16
736462 p.E545K WT 43.2 HPV 16
711012 p.E545K WT 43.5 HPV 16
738147 p.C420R p.R130G, CN Loss 45 Negative
707913 WT CN Loss 47.1 HPV 16
755439 p.E545K WT 47.1 Many
746486 WT p.T319fs 56.5 Negative
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do not activate downstream signaling via AKT to the 
same extent as similar mutations in non-obese patients. 
Increased expression of pAKT was associated with 
inferior outcome after chemo-radiation only in the non-
obese group, suggesting that AKT downstream signals 
are differentially regulated between the two groups. To 
further evaluate potential molecular mechanisms for the 
observed difference in outcome for PI3K mutant tumors in 
obese versus non-obese patients, we compared publically 
available reverse phase protein array (RPPA) data from 
The Cancer Genome Atlas Project (TCGA). In non-
obese hosts, PIK3CA and PTEN mutant tumors displayed 
significantly higher levels of phosphorylation of AKT 
at S473 and T308, key sites critical for full activation 
of AKT kinase activity. In contrast, no increase in AKT 
phosphorylation at either site was observed for PIK3CA 
and PTEN mutant tumors from patients with BMI > 35. 
Phosphorylation of downstream AKT targets PRAS40 
and TUBERIN was increased in PIK3CA and PTEN 
mutant tumors from non-obese hosts, but phosphorylation 
was not increased in PIK3CA and PTEN mutant tumors 
from patients with BMI > 35. These results suggest that 
PIK3CA and PTEN mutations more effectively activate 
AKT kinase activity and phosphorylation of select AKT 
downstream targets in cervical tumors when the patient 
is non-obese.
It is important to note that in the TCGA project 
for cervical cancer, the majority of patients were 
treated with surgery for early stage disease. When we 
compared survival outcome data from the TCGA based 
on pretreatment BMI groups, we noted a similar trend 
of improved survival outcome with obesity, however 
outcomes in the TCGA cohort did not reach statistical 
significance (p =.07, Figure 5). There are several potential 
explanations for the lack of statistical significance in 
the TCGA cohort including smaller cohort size, shorter 
median follow-up time and non-uniform treatment. The 
effects of obesity on outcome may be different for patients 
Figure 5: Overall survival outcomes from The Cancer Genome Atlas (TCGA) dataset separated by pretreatment BMI. 
Overall survival outcomes obtained from the TCGA dataset based on pretreatment BMI: BMI group: A ≤ 18 (black); B 18 – 35 (red); and 
C ≥ 35 (green), p= 0.07.
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who are managed by primary surgery versus radiation. For 
example, post-surgical complications may be increased in 
obese patients and this may obscure any protective effects 
on survival outcome. Alternatively, the protective effects 
of obesity on clinical outcomes may be more pronounced 
when patients are treated with primary radiation therapy. 
Additional study with prospectively collected clinical 
outcome databases will be needed to address this question.
While activation of the PI3K/AKT pathway is 
common in many cancers, and preclinical evidence 
for an oncogenic role for PIK3CA mutations is well 
accepted, mutations in PIK3CA have performed poorly as 
Figure 6: Phosphoprotein expression from PIK3CA and PTEN mutant tumors in obese versus non-obese hosts. Log2 
normalized phosphoprotein levels were compared for AKT_pS473, AKT_PT308, PRAS40_pT246, GSK_PS9 and Tuberin_pT1462 using 
a two tailed t-test with multiple comparison correction.
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biomarkers for outcome in solid tumors [11]. Our study 
suggests that obesity may be one factor that influences 
AKT signaling downstream of an activating PIK3CA 
mutation. PIK3CA and PTEN genomic mutations may 
be more accurate biomarkers for cervical cancer outcome 
only for patients who are non-obese. These results could 
be used to inform future clinical trial design. Stratification 
on the basis of PI3K pathway mutation may be more 
effective if the host environment is considered.
The implications of obesity and its effects on 
signaling at the molecular level are complex. How an 
obese state influences cervical tumorigenesis and the 
response to anti-cancer treatments, including irradiation, 
are incompletely understood. Our data suggest that 
cervical tumor cell signaling through the PI3K/AKT 
pathway is distinct in obese versus non-obese patients and 
that these differences are associated with the response to 
concurrent standard of care chemoradiation. Additional 
preclinical study is needed to understand how the obese 
state may influence oncogenic signaling and radiation 
responses.
MATERIALS AND METHODS
Patient databases
1) Clinical outcomes database (N=591) Patients 
in the study cohort consisted of 591 patients with a 
new diagnosis of advanced cervical cancer seen at our 
institution from June 1997 to June 2014. Pre-treatment 
BMI (calculated using the National Institute of Health 
online calculator) was recorded for all patients. All patients 
underwent a pre-treatment workup including history and 
physical, examination under anesthesia, and a whole-body 
FDG-PET/CT.
2) Immunohistochemistry cohort (N=113) 
Archived formalin-fixed, paraffin-embedded (FFPE) 
specimens were used to construct a tissue microarray. 
Prospective data collection, retrospective data collection, 
and use of FFPE specimens were performed with 
University IRB approval with waiver of informed consent 
(201603148, 201108070, 201201099, 201208101, 
201104085, and 201601055).
3) Sequencing cohort (N=91) A subset of 91 
patients were prospectively enrolled into a tumor 
banking study at the time of initial diagnosis. This study 
was approved by the Institutional Review Board and 
all patients provided informed consent for sequencing 
(201105374). Tumor biopsies and blood were obtained 
prior to treatment and stored at the Tissue Procurement 
Facility.
Radiation treatment
Definitive radiation with curative intent was 
administered in all (N=591) patients. Radiation treatment 
consisted of both external beam radiotherapy and 
intracavitary brachytherapy using techniques previously 
described [12]. The median prescribed external irradiation 
dose to the pelvic lymph nodes was 50.4 Gy. Concurrent 
chemotherapy (once weekly 40 mg/m2 cisplatin) was 
administered in 88% (N=518) patients.
Statistical analysis
Overall survival (OS) and freedom from failure (FF) 
were the primary endpoints of the study. Survival outcomes 
were measured from the completion of treatment. Failure 
was defined as cancer recurrence anywhere within the body, 
both locally within in the pelvis and distantly (sites outside 
of the radiotherapy field). BMI groups were determined 
by using existing clinical categories of obesity as defined 
by the World Health Organization. Outcome-oriented 
methods for determining cutpoints proposed by Contal 
& O’Quigley were then used to determine groups within 
our patient population. [13] For analysis of all patients 
(n=591), patients were stratified into 3 BMI groups: A ≤ 
18.5; B 18.6 – 34.9; and C ≥ 35. For the subset of patients 
undergoing mutational and IHC analysis, patients were 
stratified into only 2 groups (BMI less than or equal vs 
greater than 30) because of the smaller total number of 
patients in this subset. There were insufficient numbers of 
translational correlates in our institutional datasets from 
patients with BMI > 35 to provide meaningful statistical 
analysis. SAS v9.4 and R v3.0.3 were used for the analyses. 
P < 0.05 was set as the threshold for significance for all 
study outcomes. The Kaplan-Meier (product-limit) method 
and the Log-Rank test were used to derive time-to-event 
estimates and test for significance. Fisher’s Exact test was 
utilized to compare differences between categorical data. 
ANOVA and Independent t-tests were utilized to compare 
continuous covariates and z-test for proportions was used 
to test differences in proportions. Multivariate proportional 
hazards modeling was performed as previously described 
[14]. The final model that was constructed consisted of 
variables clinical stage, lymph node status and cervical 
tumor SUV from the pretreatment FDG-PET and BMI > 35.
Immunohistochemistry analysis
A tissue microarray (TMA) was constructed from 
pre-treatment formalin-fixed paraffin embedded (FFPE) 
tumor specimens. Punches were taken from marked areas for 
tumor content and used to construct a tissue microarray on 
MTA-1 Manual Tissue Arrayer (Beecher Instruments, Inc., 
Sun Prairie, WI). Slides were prepared from 0.6μm sections, 
deparaffinized and rehydrated per manufacturer’s protocol. 
After antigen retrieval, slides were stained with anti-phospho-
AKT antibody (Rabbit anti-human AKT-1 (phospho-S473) 
polyclonal, Spring Bioscience) per manufacturer’s protocol 
using the Ventana BenchMark ULTRA autostainer (Ventana 
Medical Systems Inc., Tuscon, AZ) using cell conditioning 
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step CC1. Slides were scanned and digitized on ScanScope 
XT (Leica Biosystems, Buffalo Grove, IL), and analyzed 
using the web-based Aperio eSlide Manager platform (Leica 
Biosystems, Buffalo Grove, IL). Staining was reviewed in 
a blinded fashion by two reviewers, and given a consensus 
score for intensity of pAKT staining as absent, weak, 
intermediate or strong intensity.
PIK3CA and PTEN sequencing
Tumor biopsies were sectioned and subjected to 
review by a pathologist. Only tumor specimens with ≥ 
60% neoplastic cellularity and <20% necrosis were used 
for further analysis. DNA was extracted from frozen tumor 
tissue using QIAamp DNA kit (Qiagen, USA) according 
to the manufacturer’s instructions. Illumina libraries 
were constructed with dual-index barcode sequences and 
enrichment was performed for target regions as previously 
described [15]. Hybridization capture sequence data from 
tumor and matched normal DNA was used to catalogue 
somatic mutations in PIK3CA and PTEN, including loss 
of heterozygosity (LOH). More specifically, sequence 
data were aligned to GRCh37-lite_WUGSC_variant_2 
(http://genome.wustl.edu/pub/reference/GRCh37-lite_
WUGSC_variant_2/) using bwa-mem (Processing Profile 
c3e6b636310547caaa9776e9aca5e4c5: bwamem-stream 
0.7.10 [-t 8]). Bams were merged using Picard 1.113 then 
deduplicated using Picard 1.113 api v6. Putative somatic 
point mutations were detected using tumor and normal 
Samtools r982 [16], Varscan 2.3.6 [17], Strelka 1.0.11, 
[18] and Somatic Sniper [19]. Putative somatic indels 
were identified using GATK (gatk-somatic-indel 5336) 
[20], Pindel 0.5 [20] and Varscan 2.3.6. Variants were 
merged and filtered as previously described. In addition, 
putative variants were filtered to remove known germline 
dbSNPs (dbSNP 137), artifacts detected in a panel of 
normal samples [21] variants with less than 8 reference-
allele-supporting reads in the Normal DNA, and less than 
two supporting reads or a less than of 10% variant allele 
fraction in the tumor. PTEN LOH predictions were made 
using VarScan 2.3.6 based on read coverage distribution 
differences between tumor and matched normal using 
methods previously published [17]. Mutation locations 
were mapped to a protein framework using the lolliplot 
function in GenVisR package (http://bioconductor.org/
package/GenVisR) implemented in R3.3.0.
Reverse phase protein array data analysis
Reverse Phase Protein Array (RPPA) Data was 
generated by the Cancer Genome Atlas (TCGA) Research 
Network [22]. Normalized level 4 RPPA data from cervical 
cancer were obtained from the Cancer Proteome Atlas 
[23]. Clinical data including weight, height, and survival 
was obtained from cbioPortal [24, 25]. Log2 normalized 
protein levels were compared using a two tailed t-test 
with multiple comparison correction (Benjamini and 
Hochber alogrithm) using Matlab (MATLAB and 
Bioinformatics Toolkit 2015b, The MathWorks, Inc., 
Natick, Massachusetts, United States).
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